Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[Autonomic nervous system alteration in multiple sclerosis patients with urinary symptoms. Clinical, urodynamic and cardiovascular study].
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings.
Neuroimmunology: Cyclosporine A and azathioprine are effective adjunctive treatments for neuromyelitis optica.
[The quality of nighttime sleep in patients with multiple sclerosis].
PDE4B as a microglia target to reduce neuroinflammation.
Interferon-γ Activates Nuclear Factor-κ B in Oligodendrocytes through a Process Mediated by the Unfolded Protein Response.
New Clues to Link Between MS Drug Tysabri and Rare Brain Disease
Development of the Cell Population in the Brain White Matter of Young Children.
Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation.
Multiple Sites of the Cleavage of 21- and 25-Mer Encephalytogenic Oligopeptides Corresponding to Human Myelin Basic Protein (MBP) by Specific Anti-MBP Antibodies from Patients with Systemic Lupus Erythematosus.
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting.
Discerning primary and secondary factors responsible for clinical fatigue in multisystem diseases.
Quantitative oxygen extraction fraction from 7-Tesla MRI phase: reproducibility and application in multiple sclerosis.
Functional plasticity of the visual system in multiple sclerosis.
Initiating oral fingolimod treatment in patients with multiple sclerosis.
Molecular triggers of neuroinflammation in mouse models of demyelinating diseases.
[Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)].
Multiple Sclerosis from Bench to Bedside.
Central nervous system B-cell lymphoma in multiple sclerosis.
Autonomic dysreflexia in acute disseminated encephalomyelitis.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning.
Fluoxetin Upregulates Connexin 43 Expression in Astrocyte.
A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis.
Neuromyelitis optica.
Pages
« first
‹ previous
…
329
330
331
332
333
334
335
336
337
…
next ›
last »